[1] 王晨,马秉灵.食管癌微创外科治疗的研究进展[J].现代医学,2021,49(8):990-994.
[2] SHORT M W,BURGERS K G,FRY V T.Esophageal Cancer[J].Am Fam Physician,2017,95(1):22-28.
[3] 翟文萍,董超男,王雪野.胃癌相关炎症因子研究进展[J].医学综述,2020,26(7):1314-1318,1324.
[4] CRUSZ S M,BALKWILL F R.Inflammation and cancer:advances and new agents[J].Nat Rev Clin Oncol,2015,12(10):584-596.
[5] HOU J,KARIN M,SUN B.Targeting cancer-promoting inflammation-have anti-inflammatory therapies come of age?[J].Nat Rev Clin Oncol,2021,18(5):261-279.
[6] JIANG Y,XU D,SONG H,et al.Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer:a systematic review and Meta-analysis[J].BMJ Open,2021,11(9):e048324.
[7] KAN L L,CHAN B C,LEUNG P C,et al.Natural-product-derived adjunctive treatments to conventional therapy and their immunoregulatory activities in triple-negative breast cancer[J].Molecules,2023,28(15):5804.
[8] KHAWAR M B,ABBASI M H,SHEIKH N.IL-32:a novel pluripotent inflammatory interleukin,towards gastric inflammation,gastric cancer,and chronic rhino sinusitis[J].Mediators Inflamm,2016,2016:8413768.
[9] ROSE-JOHN S.Interleukin-6 family cytokines[J].Cold Spring Harb Perspect Biol,2018,10(2):a028415.
[10] WANG J,LI Q,CHENG X,et al.Bone marrow-derived myofibroblasts promote gastric cancer metastasis by activating TGF-β1 and IL-6/STAT3 signalling loop[J].Onco Targets Ther,2020,13:10567-10580.
[11] PASTREZ P R A,BARBOSA A M,MARIANO V S,et al.Interleukin-8 and interleukin-6 are biomarkers of poor prognosis in esophageal squamous cell carcinoma[J].Cancers(Basel),2023,15(7):1997.
[12] LIPPITZ B E,HARRIS R A.Cytokine patterns in cancer patients:a review of the correlation between interleukin 6 and prognosis[J].Oncoimmunology,2016,5(5):e1093722.
[13] QIAO Y,ZHANG C,LI A,et al.IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma[J].Oncogene,2018,37(7):873-883.
[14] MAEDA Y,TAKEUCHI H,MATSUDA S,et al.Clinical significance of preoperative serum concentrations of interleukin-6 as a prognostic marker in patients with esophageal cancer[J].Esophagus,2020,17(3):279-288.
[15] HASSAN M S,CWIDAK N,AWASTHI N,et al.Cytokine interaction with cancer-associated fibroblasts in esophageal cancer[J].Cancer Control,2022,29:10732748221078470.
[16] LIU Q,LI A,TIAN Y,et al.The CXCL8-CXCR1/2 pathways in cancer[J].Cytokine Growth Factor Rev,2016,31:61-71.
[17] DU J,HE Y,LI P,et al.IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1(MDR1)[J].Cancer Chemother Pharmacol,2018,81(6):1111-1119.
[18] OGURA M,TAKEUCHI H,KAWAKUBO H,et al.Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma[J].Surgery,2013,154(3):512-520.
[19] LIN X,WANG S,SUN M,et al.miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization[J].J Hematol Oncol,2019,12(1):20.
[20] MONTERAN L,EREZ N.The dark side of fibroblasts:cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment[J].Front Immunol,2019,10:1835.
[21] LI J,ZHANG B Z,QIN Y R,et al.CD68 and interleukin 13,prospective immune markers for esophageal squamous cell carcinoma prognosis prediction[J].Oncotarget,2016,7(13):15525-15538.
[22] VASILEV G,IVANOVA M,STANILOV I,et al.Influence of IL10 and TGFB1 promoter polymorphisms on serum cytokine levels in development and severity of RA[J].Int J Mol Sci,2022,23(19):11955.
[23] DU G H,WANG J K,RICHARDS J R,et al.Genetic polymorphisms in tumor necrosis factor alpha and interleukin-10 are associated with an increased risk of cervical cancer[J].Int Immunopharmacol,2019,66:154-161.
[24] PERUCHA E,MELCHIOTTI R,BIBBY J A,et al.The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells[J].Nat Commun,2019,10(1):498.
[25] SUN J M,LI Q,GU H Y,et al.Interleukin 10 rs1800872 T>G polymorphism was associated with an increased risk of esophageal cancer in a Chinese population[J].Asian Pac J Cancer Prev,2013,14(6):3443-3447.
[26] MARSHALL E A,NG K W,KUNG S H,et al.Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis[J].Mol Cancer,2016,15(1):67.
[27] AMICARELLA F,MURARO M G,HIRT C,et al.Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer[J].Gut,2017,66(4):692-704.
[28] SONG Y,YANG J M.Role of interleukin(IL)-17 and T-helper(Th)17 cells in cancer[J].Biochem Biophys Res Commun,2017,493(1):1-8.
[29] SANKALECHA T H,GUPTA S J,GAIKWAD N R,et al.Yield of p53 expression in esophageal squamous cell cancer and its relationship with survival[J].Saudi J Gastroenterol,2017,23(5):281-286.
[30] YE F,SONG J,WANG Y,et al.Proliferation potential-related protein promotes the esophageal cancer cell proliferation,migration and suppresses apoptosis by mediating the expression of p53 and interleukin-17[J].Pathobiology,2018,85(5-6):322-331.
[31] HAN S,YANG Y.Interleukin-32:frenemy in cancer?[J].BMB Rep,2019,52(3):165-174.
[32] HE J,YE W,KOU N,et al.MicroRNA-29b-3p suppresses oral squamous cell carcinoma cell migration and invasion via IL32/AKT signalling pathway[J].J Cell Mol Med,2020,24(1):841-849.
[33] YANG J,JIAN Z,SHEN P,et al.Associations between interleukin-32 gene polymorphisms rs12934561 and rs28372698 and susceptibilities to bladder cancer and the prognosis in Chinese Han population[J].Dis Markers,2020,2020:8860445.
[34] DIAKOWSKA D,KRZYSTEK-KORPACKA M.Local and systemic interleukin-32 in esophageal,gastric,and colorectal cancers:clinical and diagnostic significance[J].Diagnostics(Basel),2020,10(10).
[35] WANG S,CHEN F,TANG L.IL-32 promotes breast cancer cell growth and invasiveness[J].Oncol Lett,2015,9(1):305-307.
[36] LIAN J,LIN D,HUANG Y,et al.Exploring the potential use of Chinese herbs in regulating the inflammatory microenvironment of tumours based on the concept of 'state-target identification and treatment’:a scooping review[J].Chin Med,2023,18(1):124.
[37] ZAREMBA-CZOGALLA M,HRYNIEWICZ-JANKOWSKA A,TABOLA R,et al.A novel regulatory function of CDKN1A/p21 in TNFα-induced matrix metalloproteinase 9-dependent migration and invasion of triple-negative breast cancer cells[J].Cell Signal,2018,47:27-36.
[38] FRANCZAK M A,KROL O,HARASIM G,et al.Metabolic effects of new glucose transporter(GLUT-1) and lactate dehydrogenase-A(LDH-A) inhibitors against chemoresistant malignant mesothelioma[J].Int J Mol Sci,2023,24(9):7771.
[39] AUGOFF K,HRYNIEWICZ-JANKOWSKA A,TABOLA R,et al.MMP9:a tough target for targeted therapy for cancer[J].Cancers(Basel),2022,14(7):1847.
[40] HAY N.Reprogramming glucose metabolism in cancer:can it be exploited for cancer therapy?[J].Nat Rev Cancer,2016,16(10):635-649.
[41] LIBERTI M V,LOCASALE J W.The Warburg effect:how does it benefit cancer cells?[J].Trends Biochem Sci,2016,41(3):211-218.
[42] VAUGHAN R A,GARCIA-SMITH R,TRUJILLO K A,et al.Tumor necrosis factor alpha increases aerobic glycolysis and reduces oxidative metabolism in prostate epithelial cells[J].Prostate,2013,73(14):1538-1546.
[43] FORKASIEWICZ A,STACH W,WIERZBICKI J,et al.Effect of LDHA inhibition on TNF-α-induced cell migration in esophageal cancers[J].Int J Mol Sci,2022,23(24):16062.
[44] 郭欣,张科科,刘燕,等.IGF信号轴在卵巢癌干细胞样细胞增殖状态转换及预防卵巢癌复发中的作用[J].东南大学学报(医学版),2016,35(5):736-741.
[45] ADACHI Y,NOJIMA M,MORI M,et al.Insulin-like growth factor-1,IGF binding protein-3,and the risk of esophageal cancer in a nested case-control study[J].World J Gastroenterol,2017,23(19):3488-3495.
[46] XU W W,LI B,GUAN X Y,et al.Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression[J].Nat Commun,2017,8:14399.
[47] BARROCA V,LEWANDOWSKI D,JARACZ-ROS A,et al.Paternal insulin-like growth factor 2(Igf2) regulates stem cell activity during adulthood[J].EBioMedicine,2017,15:150-162.
[48] XU W W,LI B,ZHAO J F,et al.IGF2 induces CD133 expression in esophageal cancer cells to promote cancer stemness[J].Cancer Lett,2018,425:88-100.
[49] PAPAGEORGIS P.TGFβ signaling in tumor initiation,epithelial-to-mesenchymal transition,and metastasis[J].J Oncol,2015,2015:587193.
[50] GOUGH N R,XIANG X,MISHRA L.TGF-β signaling in liver,pancreas,and gastrointestinal diseases and cancer[J].Gastroenterology,2021,161(2):434-452.e415.
[51] LUO K.Signaling cross talk between TGF-β/smad and other signaling pathways[J].Cold Spring Harb Perspect Biol,2017,9(1):a022137.
[52] ZHANG Y,ALEXANDER P B,WANG X F.TGF-β family signaling in the control of cell proliferation and survival[J].Cold Spring Harb Perspect Biol,2017,9(4):a022145.
[53] SONG W,DAI W J,ZHANG M H,et al.Comprehensive analysis of the expression of TGF-β signaling regulators and prognosis in human esophageal cancer[J].Comput Math Methods Med,2021,2021:1812227.
[54] MOREIN D,ERLICHMAN N,BEN-BARUCH A.Beyond cell motility:the expanding roles of chemokines and their receptors in malignancy[J].Front Immunol,2020,11:952.
[55] 赵琪.血清CXC趋化因子对非小细胞肺癌诊断价值的研究[D].保定：河北大学,2016.
[56] DANIEL S K,SEO Y D,PILLARISETTY V G.The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies[J].Semin Cancer Biol,2020,65:176-188.
[57] WU X,ZHANG H,SUI Z,et al.The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma[J].Cancer Biol Med,2021,18(2):401-410.
[58] GOTO M,YOSHIDA T,YAMAMOTO Y,et al.CXCR4 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma[J].Springer International Publishing,2017,(3)：832-840.
[59] KORBECKI J,KOJDER K,KAPCZUK P,et al.The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors-a review of literature[J].Int J Mol Sci,2021,22(2)：843.
[60] GOTO M,LIU M.Chemokines and their receptors as biomarkers in esophageal cancer[J].Esophagus,2020,17(2):113-121.
[61] 姜婧琦,宋雨童,卢育彤,等.抗血管生成靶向药物在肿瘤治疗中的研究进展[J].山东医药,2022,62(22):86-90.
[62] JIANG F,CHONG L,DU S,et al.Decreased ratio of VEGF165b/VEGF in aqueous humor predicts progression of diabetic retinopathy[J].Ophthalmic Res,2020,63(6):517-523.
[63] ZENG Y Z,ZHANG Y Q,LIN X Q,et al.Co-expression of VEGF-C and survivin predicts poor prognosis in esophageal squamous cell carcinoma[J].Transl Cancer Res,2021,10(1):210-222.
[64] KONG R,MA Y,FENG J,et al.The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A[J].Cell Mol Biol Lett,2016,21:3.
[65] SAKAEDA T,YAMAMORI M,KUWAHARA A,et al.VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients[J].Ther Drug Monit,2008,30(4):497-503. |
